Central Retinal Vein Occlusion Market

DelveInsight's "Central Retinal Vein Occlusion Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Central Retinal Vein Occlusion, historical and forecasted epidemiology as well as the Central Retinal Vein Occlusion market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

The Central Retinal Vein Occlusion market report provides current treatment practices, emerging drugs, Central Retinal Vein Occlusion market share of the individual therapies, current and forecasted Central Retinal Vein Occlusion market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Central Retinal Vein Occlusion treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Central Retinal Vein Occlusion market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

 

Study Period: 2019-2032

Central Retinal Vein Occlusion Disease Understanding and Treatment Algorithm

The DelveInsight’s Central Retinal Vein Occlusion market report gives a thorough understanding of the Central Retinal Vein Occlusion by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis, and treatment.

 

Central retinal vein occlusion (CRVO) is an occlusion of the main retinal vein posterior to the lamina cribrosa of the optic nerve and is typically caused by thrombosis. The pathogenesis of CRVO is believed to involve vascular endothelial damage and compression of the retinal vein, leading to thrombus formation and retinal capillary pressure. It can be a debilitating and devastating disease, in which the venous occlusion induces an ischemic and hypoxic state that leads to visually significant squeal including macular edema, anterior segment and retinal neovascularization.

 

Central Retinal Vein Occlusion Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Central Retinal Vein Occlusion.

 

Central Retinal Vein Occlusion Treatment

It covers the details of conventional and current medical therapies available in the Central Retinal Vein Occlusion market for the treatment of the condition. It also provides Central Retinal Vein Occlusion treatment algorithms and guidelines in the United States, Europe, and Japan.

Central Retinal Vein Occlusion Epidemiology 

The Central Retinal Vein Occlusion epidemiology section provides insights about the historical and current Central Retinal Vein Occlusion patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Central Retinal Vein Occlusion market report also provides the diagnosed patient pool and their trends along with assumptions undertaken. 

 

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Central Retinal Vein Occlusion epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

  • Retinal vein occlusion (RVO) is the second most common sight-threatening retinal vascular disorder after diabetic retinopathy, and includes two types, central RVO and branch RVO depending on the site of occlusion. Central retinal vein occlusion is one of the leading causes of sudden, painless vision loss in adults,
  • with prevalence ~ 0.8 per 1000. (Rogers S et al.)
  • Overall, the prevalence of CRVO appears to be relatively constant across all countries, globally, an estimated 2.5 million adults are affected by CRVO (Lauori M et al.). Prevalence rates are similar across the world, ranging between 0.3% and 2.1% in data collected from international epidemiological studies.
  • According to the literature review, non-ischemic CRVO is the most common, accounting for about 70% of cases whereas Ischemic CRVO has a much lower visual prognosis and accounts for about 30% of cases. Ischemic CRVO can be primary or progression of a non-ischemic CRVO.
  • According to the Beaver Dam Eye Study, the 15-year cumulative occurrence of central retinal vein occlusion was 0.5%, and reported that CRVO is less common than BRVO (Branch Retinal Vein Occlusion). Prevalence did not differ by gender.
  • According to the literature review, age is one of the major risk factor for the development of CRVO and approximately 90% of patients are older than 50 years. (Kyle Blair et al.)

 

Country Wise- Central Retinal Vein Occlusion Epidemiology

The epidemiology segment also provides the Central Retinal Vein Occlusion epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Central Retinal Vein Occlusion Drug Chapters

The drug chapter segment of the Central Retinal Vein Occlusion report encloses the detailed analysis of Central Retinal Vein Occlusion marketed drugs and late-stage (Phase-III and Phase-II) Central Retinal Vein Occlusion pipeline drugs. It also helps to understand the Central Retinal Vein Occlusion clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

 

Central Retinal Vein Occlusion Marketed Drugs

The report provides the details of the marketed products/off-label treatments available for Central Retinal Vein Occlusion treatment.

 

  • Eylea (aflibercept): Regeneron Pharmaceuticals
  • And Others

 

Central Retinal Vein Occlusion Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Central Retinal Vein Occlusion treatment.

 

  • Brolucizumab : Novartis
  • Conbercept : Chengdu Kanghong Biotech
  • Hydroxycarbamid : Addmedica
  • And Others

Central Retinal Vein Occlusion Market Outlook

The Central Retinal Vein Occlusion market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Central Retinal Vein Occlusion market trends by analyzing the impact of current Central Retinal Vein Occlusion therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of Central Retinal Vein Occlusion market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Central Retinal Vein Occlusion market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Central Retinal Vein Occlusion market in 7MM is expected to witness a major change in the study period 2019-2032.

 

Key Findings

This section includes a glimpse of the Central Retinal Vein Occlusion market in 7MM.

 

The United States Central Retinal Vein Market Outlook

This section provides the total Central Retinal Vein Occlusion market size and market size by therapies in the United States.

 

EU-5 Countries: Central Retinal Vein Market Outlook

The total Central Retinal Vein Occlusion market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

 

Japan Central Retinal Vein Market Outlook

The total Central Retinal Vein Occlusion market size and market size by therapies in Japan is also mentioned.

Central Retinal Vein Occlusion Drugs Uptake

This section focuses on the rate of uptake of the potential Central Retinal Vein Occlusion drugs recently launched in the Central Retinal Vein Occlusion market or expected to get launched in the market during the study period 2019-2032. The analysis covers Central Retinal Vein Occlusion market uptake by drugs; patient uptake by therapies; and sales of each drug.   

Central Retinal Vein Occlusion Drugs Uptake helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allow the comparison of the drugs on the basis of Central Retinal Vein Occlusion market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

 

Central Retinal Vein Occlusion Pipeline Development Activities

The Central Retinal Vein Occlusion report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Central Retinal Vein Occlusion key players involved in developing targeted therapeutics.

 

Pipeline Development Activities

The Central Retinal Vein Occlusion report covers the detailed information of collaborations, acquisition, and merger, licensing, patent details, and other information for Central Retinal Vein Occlusion emerging therapies.

Reimbursement Scenario in Central Retinal Vein Occlusion

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current Central Retinal Vein Occlusion market trends, we take KOLs and SMEs ' opinion working in the Central Retinal Vein Occlusion domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Central Retinal Vein Occlusion market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Central Retinal Vein Occlusion Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Central Retinal Vein Market Report

  • The report covers the descriptive overview of Central Retinal Vein Occlusion, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Central Retinal Vein Occlusion epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Central Retinal Vein Occlusion is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of the Central Retinal Vein Occlusion market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Central Retinal Vein Occlusion market
Report Attribute/Metric Details
Study Period 2019- 2032
Geographies Covered 7MM
Market Size USD XX Miliion
CAGR XX%
Key Companies
  • Novartis
  • Chengdu Kanghong Biotech
  • Addmedica
  • Regeneron Pharmaceuticals

Central Retinal Vein Report Highlights

  • In the coming years, the Central Retinal Vein Occlusion market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Central Retinal Vein Occlusion R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition      
  • Major players are involved in developing therapies for Central Retinal Vein Occlusion. The launch of emerging therapies will significantly impact the Central Retinal Vein Occlusion market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Central Retinal Vein Occlusion
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Central Retinal Vein Occlusion Report Insights

  • Central Retinal Vein Occlusion Patient Population
  • Therapeutic Approaches
  • Central Retinal Vein Occlusion Pipeline Analysis
  • Central Retinal Vein Occlusion Market Size
  • Central Retinal Vein Market Trends
  • Central Retinal Vein Occlusion Market Opportunities
  • Impact of upcoming Central Retinal Vein Occlusion Therapies

Central Retinal Vein Occlusion Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage
  • Central Retinal Vein Occlusion Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Central Retinal Vein Market
  • Central Retinal Vein Drugs Uptake

Central Retinal Vein Occlusion Report Assessment

  • Current Treatment Practices
  • Central Retinal Vein Unmet Needs
  • Central Retinal Vein Occlusion Pipeline Product Profiles
  • Central Retinal Vein Occlusion Market Attractiveness
  • Central Retinal Vein Market Drivers
  • Central Retinal Vein Market Barriers

Key Questions

Central Retinal Vein Market Insights:

  • What was the Central Retinal Vein Occlusion drug class share (%) distribution in 2019 and how it would look like in 2032?
  • What would be the Central Retinal Vein Occlusion total market size as well as market size by therapies across the 7MM during the forecast period (2019-2032)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Central Retinal Vein Occlusion market size during the forecast period (2019-2032)?
  • At what CAGR, the Central Retinal Vein Occlusion market is expected to grow by 7MM during the forecast period (2019-2032)?
  • What would be the Central Retinal Vein Occlusion market outlook across the 7MM during the forecast period (2019-2032)?
  • What would be the Central Retinal Vein Occlusion market growth till 2032, and what will be the resultant market Size in the year 2032?
  • How would the unmet needs affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What are the disease risk, burden, and regional/ethnic differences of the Central Retinal Vein Occlusion?
  • What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What is the historical Central Retinal Vein Occlusion patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Central Retinal Vein Occlusion in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • Where will be the growth opportunities in the 7MM with respect to the patient population pertaining to Central Retinal Vein Occlusion?
  • Out of all 7MM countries, which country would have the highest prevalent population of Central Retinal Vein Occlusion during the forecast period (2019-2032)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2019-2032)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

  • What are the current options for the Central Retinal Vein Occlusion treatment in addition to the approved therapies?
  • What are the current treatment guidelines for the treatment of Central Retinal Vein Occlusion in the USA, Europe, and Japan?
  • What are the Central Retinal Vein Occlusion marketed drugs and their respective MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Central Retinal Vein Occlusion?
  • How many therapies are in-development by each company for Central Retinal Vein Occlusion treatment?
  • How many are emerging therapies in mid-stage, and late stage of development for Central Retinal Vein Occlusion treatment?
  • What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Central Retinal Vein Occlusion therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies being developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Central Retinal Vein Occlusion and their status?
  • What are the current challenges faced in drug development?
  • What are the key designations that have been granted for the emerging therapies for Central Retinal Vein Occlusion?
  • What are the global historical and forecasted market of Central Retinal Vein Occlusion?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Central Retinal Vein Occlusion market
  • To understand the future market competition in the Central Retinal Vein Occlusion market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Central Retinal Vein Occlusion in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Central Retinal Vein Occlusion market
  • To understand the future market competition in the Central Retinal Vein Occlusion market

1. Key Insights

2. Executive Summary of Central Retinal Vein Occlusion

3. Competitive Intelligence Analysis for Central Retinal Vein Occlusion

4. Central Retinal Vein Occlusion: Market Overview at a Glance

4.1. Central Retinal Vein Occlusion Total Market Share (%) Distribution in 2019

4.2. Central Retinal Vein Occlusion Total Market Share (%) Distribution in 2032

5. Central Retinal Vein Occlusion: Disease Background and Overview

5.1. Introduction

5.2. Sign and Symptoms

5.3. Pathophysiology

5.4. Risk Factors

5.5. Diagnosis

6. Patient Journey

7. Central Retinal Vein Occlusion Epidemiology and Patient Population

7.1. Epidemiology Key Findings

7.2. Assumptions and Rationale: 7MM

7.3. Epidemiology Scenario: 7MM

7.3.1. Central Retinal Vein Occlusion Epidemiology Scenario in the 7MM (2019-2032)

7.4. United States Epidemiology

7.4.1. Central Retinal Vein Occlusion Epidemiology Scenario in the United States (2019-2032)

7.5. EU-5 Country-wise Epidemiology

7.5.1. Germany Epidemiology

7.5.1.1. Central Retinal Vein Occlusion Epidemiology Scenario in Germany (2019-2032)

7.5.2. France Epidemiology

7.5.2.1. Central Retinal Vein Occlusion Epidemiology Scenario in France (2019-2032)

7.5.3. Italy Epidemiology

7.5.3.1. Central Retinal Vein Occlusion Epidemiology Scenario in Italy (2019-2032)

7.5.4. Spain Epidemiology

7.5.4.1. Central Retinal Vein Occlusion Epidemiology Scenario in Spain (2019-2032)

7.5.5. United Kingdom Epidemiology

7.5.5.1. Central Retinal Vein Occlusion Epidemiology Scenario in the United Kingdom (2019-2032)

7.5.6. Japan Epidemiology

7.5.6.1. Central Retinal Vein Occlusion Epidemiology Scenario in Japan (2019-2032)

8. Treatment Algorithm, Current Treatment, and Medical Practices

8.1. Central Retinal Vein Occlusion Treatment and Management

8.2. Central Retinal Vein Occlusion Treatment Algorithm

9. Central Retinal Vein Occlusion Unmet Needs

10. Key Endpoints of Central Retinal Vein Occlusion Treatment

11. Central Retinal Vein Occlusion Marketed Products

11.1. List of Central Retinal Vein Occlusion Marketed Drugs in the 7MM

11.2. Drug Name: Company Name

11.2.1. Product Description

11.2.2. Regulatory Milestones

11.2.3. Other Developmental Activities

11.2.4. Pivotal Clinical Trials

11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Central Retinal Vein Occlusion Emerging Therapies

12.1. Key Cross

12.2. Drug Name: Company Name

12.2.1. Product Description

12.2.2. Other Developmental Activities

12.2.3. Clinical Development

12.2.4. Safety and Efficacy

12.2.5. Product Profile

List to be continued in report

13. Central Retinal Vein Occlusion: Seven Major Market Analysis

13.1. Key Findings

13.2. Central Retinal Vein Occlusion Market Size in 7MM

13.3. Central Retinal Vein Occlusion Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Central Retinal Vein Market Outlook

15.1. United States: Central Retinal Vein Market Size

15.1.1. Central Retinal Vein Occlusion Total Market Size in the United States

15.1.2. Central Retinal Vein Occlusion Market Size by Therapies in the United States

15.2. EU-5 countries: Central Retinal Vein Market Size and Outlook

15.3. Germany Central Retinal Vein Market Size

15.3.1. Central Retinal Vein Occlusion Total Market Size in Germany

15.3.2. Central Retinal Vein Occlusion Market Size by Therapies in Germany

15.4. France Central Retinal Vein Market Size

15.4.1. Central Retinal Vein Occlusion Total Market Size in France

15.4.2. Central Retinal Vein Occlusion Market Size by Therapies in France

15.5. Italy Central Retinal Vein Market Size

15.5.1. Central Retinal Vein Occlusion Total Market Size in Italy

15.5.2. Central Retinal Vein Occlusion Market Size by Therapies in Italy

15.6. Spain Central Retinal Vein Market Size

15.6.1. Central Retinal Vein Occlusion Total Market Size in Spain

15.6.2. Central Retinal Vein Occlusion Market Size by Therapies in Spain

15.7. United Kingdom Central Retinal Vein Market Size

15.7.1. Central Retinal Vein Occlusion Total Market Size in the United Kingdom

15.7.2. Central Retinal Vein Occlusion Market Size by Therapies in the United Kingdom

15.8. Japan Central Retinal Vein Market Outlook

15.8.1. Japan Central Retinal Vein Market Size

15.8.2. Central Retinal Vein Occlusion Total Market Size in Japan

15.8.3. Central Retinal Vein Occlusion Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Central Retinal Vein Occlusion

17. KOL Views

18. Central Retinal Vein Market Drivers

19. Central Retinal Vein Market Barriers

20. Appendix

20.1. Bibliography

20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

*The table of contents is not exhaustive; the final content may vary.

List of Table

Table 1: 7MM Central Retinal Vein Occlusion Epidemiology (2019-2032)

Table 2: 7MM Central Retinal Vein Occlusion Diagnosed and Treatable Cases (2019-2032)

Table 3: Central Retinal Vein Occlusion Epidemiology in the United States (2019-2032)

Table 4: Central Retinal Vein Occlusion Diagnosed and Treatable Cases in the United States (2019-2032)

Table 5: Central Retinal Vein Occlusion Epidemiology in Germany (2019-2032)

Table 6: Central Retinal Vein Occlusion Diagnosed and Treatable Cases in Germany (2019-2032)

Table 7: Central Retinal Vein Occlusion Epidemiology in France (2019-2032)

Table 8: Central Retinal Vein Occlusion Diagnosed and Treatable Cases in France (2019-2032)

Table 9: Central Retinal Vein Occlusion Epidemiology in Italy (2019-2032)

Table 10: Central Retinal Vein Occlusion Diagnosed and Treatable Cases in Italy (2019-2032)

Table 11: Central Retinal Vein Occlusion Epidemiology in Spain (2019-2032)

Table 12: Central Retinal Vein Occlusion Diagnosed and Treatable Cases in Spain (2019-2032)

Table 13: Central Retinal Vein Occlusion Epidemiology in the UK (2019-2032)

Table 14: Central Retinal Vein Occlusion Diagnosed and Treatable Cases in the UK (2019-2032)

Table 15: Central Retinal Vein Occlusion Epidemiology in Japan (2019-2032)

Table 16: Central Retinal Vein Occlusion Diagnosed and Treatable Cases in Japan (2019-2032)

Table 17: Drug Name, Clinical Trials by Recruitment status

Table 18: Drug Name, Clinical Trials by Zone

Table 19: Total Seven Major Market Size in USD, Million (2019-2032)

Table 20: Region-wise Market Size in USD, Million (2019-2032)

Table 21: 7MM-Market Size by Therapy in USD, Million (2019-2032)

Table 22: United States Market Size in USD, Million (2019-2032)

Table 23: United States Market Size by Therapy in USD, Million (2019-2032)

Table 24: Germany Market Size in USD, Million (2019-2032)

Table 25: Germany Market Size by Therapy in USD, Million (2019-2032)

Table 26: France Market Size in USD, Million (2019-2032)

Table 27: France Market Size by Therapy in USD, Million (2019-2032)

Table 28: Italy Market Size in USD, Million (2019-2032)

Table 29: Italy Market Size by Therapy in USD, Million (2019-2032)

Table 30: Spain Market Size in USD, Million (2019-2032)

Table 31: Spain Market Size by Therapy in USD, Million (2019-2032)

Table 32: United Kingdom Market Size in USD, Million (2019-2032)

Table 33: United Kingdom Market Size by Therapy in USD, Million (2019-2032)

Table 34: Japan Market Size in USD, Million (2019-2032)

Table 35: Japan Market Size by Therapy in USD, Million (2019-2032)

*The list of tables is not exhaustive; the final content may vary

List of Figures

Figure 1: 7MM Central Retinal Vein Occlusion Epidemiology (2019-2032)

Figure 2: 7MM Central Retinal Vein Occlusion Diagnosed and Treatable Cases (2019-2032)

Figure 3: Central Retinal Vein Occlusion Epidemiology in the United States (2019-2032)

Figure 4: Central Retinal Vein Occlusion Diagnosed and Treatable Cases in the United States (2019-2032)

Figure 5: Central Retinal Vein Occlusion Epidemiology in Germany (2019-2032)

Figure 6: Central Retinal Vein Occlusion Diagnosed and Treatable Cases in Germany (2019-2032)

Figure 7: Central Retinal Vein Occlusion Epidemiology in France (2019-2032)

Figure 8: Central Retinal Vein Occlusion Diagnosed and Treatable Cases in France (2019-2032)

Figure 9: Central Retinal Vein Occlusion Epidemiology in Italy (2019-2032)

Figure 10: Central Retinal Vein Occlusion Diagnosed and Treatable Cases in Italy (2019-2032)

Figure 11: Central Retinal Vein Occlusion Epidemiology in Spain (2019-2032)

Figure 12: Central Retinal Vein Occlusion Diagnosed and Treatable Cases in Spain (2019-2032)

Figure 13: Central Retinal Vein Occlusion Epidemiology in the UK (2019-2032)

Figure 14: Central Retinal Vein Occlusion Diagnosed and Treatable Cases in the UK (2019-2032)

Figure 15: Central Retinal Vein Occlusion Epidemiology in Japan (2019-2032)

Figure 16: Central Retinal Vein Occlusion Diagnosed and Treatable Cases in Japan (2019-2032)

Figure 17: Drug Name, Clinical Trials by Recruitment status

Figure 18: Drug Name, Clinical Trials by Zone

Figure 19: Total Seven Major Market Size in USD, Million (2019-2032)

Figure 20: Region-wise Market Size in USD, Million (2019-2032)

Figure 21: 7MM-Market Size by Therapy in USD, Million (2019-2032)

Figure 22: United States Market Size in USD, Million (2019-2032)

Figure 23: United States Market Size by Therapy in USD, Million (2019-2032)

Figure 24: Germany Market Size in USD, Million (2019-2032)

Figure 25: Germany Market Size by Therapy in USD, Million (2019-2032)

Figure 26: France Market Size in USD, Million (2019-2032)

Figure 27: France Market Size by Therapy in USD, Million (2019-2032)

Figure 28: Italy Market Size in USD, Million (2019-2032)

Figure 29: Italy Market Size by Therapy in USD, Million (2019-2032)

Figure 30: Spain Market Size in USD, Million (2019-2032)

Figure 31: Spain Market Size by Therapy in USD, Million (2019-2032)

Figure 32: United Kingdom Market Size in USD, Million (2019-2032)

Figure 33: United Kingdom Market Size by Therapy in USD, Million (2019-2032)

Figure 34: Japan Market Size in USD, Million (2019-2032)

Figure 35: Japan Market Size by Therapy in USD, Million (2019-2032)

*The list of figures is not exhaustive; the final content may vary

  • Brolucizumab : Novartis
  • Conbercept : Chengdu Kanghong Biotech
  • Hydroxycarbamid : Addmedica
  • Eylea (aflibercept): Regeneron Pharmaceuticals

Forward to Friend

Need A Quote